Login
$KYTX
$4.79 -$0.26 (5.15%) Live

$KYTX SEC Filings

Filed On Filing
16 Nov 2026 SCHEDULE 13G/A
12 Nov 2026 10-Q
12 Nov 2026 8-K: Results of Operations and Financial Condition

Kyverna Therapeutics Announces Completion of BLA Submission for Miv-cel in Stiff Person Syndrome and Reports Third Quarter 2026 Financial Results

19 Oct 2026 SCHEDULE 13G
24 Sep 2026 8-K: Regulation FD Disclosure

Kyverna Therapeutics Reports Positive One-Year Data Demonstrating Durable Clinical Responses and Favorable Safety Profile for Miv-cel in Stiff Person Syndrome and Generalized Myasthenia Gravis

14 Aug 2026 SCHEDULE 13G/A
11 Aug 2026 10-Q
11 Aug 2026 8-K: Results of Operations and Financial Condition

FDA grants RMAT designation for miv-cel in non-active secondary progressive multiple sclerosis (naSPMS) based on compelling clinical data, further expanding the therapy’s potential across neuroimmunology

29 Jul 2026 SCHEDULE 13G
27 Jul 2026 8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure

New agreement secures flexible and scalable manufacturing to support the U.S. commercial and global clinical supply of miv-cel

09 Jul 2026 8-K: Entry into a Material Definitive Agreement

As previously disclosed, on October 31, 2025, Kyverna Therapeutics, Inc. (the “Company”) entered into that certain Loan and Security Agreement (the “Loan and Security Agreement”) with Oxford Finance LLC, as collateral agent (the “Collate...

02 Jun 2026 8-K: Submission of Matters to a Vote of Security Holders

On May 27, 2026, Kyverna Therapeutics, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”). Of the 60,530,293 shares of the Company’s common stock outstanding as of March 30, 2026, the record date for...

29 May 2026 Form 4: Clark Ian T, Director

Received 5,093 shares as a grant or award · Granted 20,582 Stock Option (right to buy)

29 May 2026 Form 4: Cohen Fred E, Director

Received 5,093 shares as a grant or award · Granted 20,582 Stock Option (right to buy)

29 May 2026 Form 4: Seidenberg Beth C, Director

Received 5,093 shares as a grant or award · Granted 20,582 Stock Option (right to buy)

29 May 2026 Form 4: Shaw Christi, Director

Gave up 4,194 shares to cover exercise price or tax ($36K)

29 May 2026 Form 4: Aktar Mert, Director

Received 5,093 shares as a grant or award · Granted 20,582 Stock Option (right to buy)

20 May 2026 Form 4: Martini Gregory S., Chief Financial Officer

Granted 325,000 Stock Option (right to buy)

20 May 2026 Form 3: Martini Gregory S., Chief Financial Officer

No securities owned

18 May 2026 8-K: Departure/Election of Directors or Officers; Compensation; Other Events

Kyverna Therapeutics, Inc. (the “Company”) is pleased to offer you employment beginning on May 18, 2026 (the “Start Date”); provided, however, if your employment does not commence on the Start Date, this letter shall be null and void and...

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support